Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA


Por: Plaza, V, Domínguez-Ortega, J, Alsina, DGS, Lo Re, D, Sicras-Mainar, A

Publicada: 1 nov 2023
Resumen:
Introduction: Adding LAMA to LABA/ICS is recommended to improve control in patients with persistent asthma. Methods: This observational, retrospective, before-and-after study considered patients diagnosed with asthma who started LABA/ICS + LAMA treatment (triple therapy, TT) between 1 January 2017 and 31 December 2018 and had been treated with LABA/ICS (dual therapy, DT) in the year before. Changes in lung function and exacerbation rates, healthcare resource utilization, and healthcare and non-healthcare costs (2019) were estimated in patients with asthma in clinical practices in Spain. Data from computerized medical records from seven Spanish regions were collected +/- 1 year of LAMA addition. Results: 4740 patients (64.1 years old [SD: 16.3]) were included. TT reduced the incidence of exacerbations by 16.7% (p < 0.044) and the number of patients with exacerbations by 8.5% (p < 0.001) compared to previous DT. The rate of patients with severe exacerbations requiring systemic corticosteroids and their hospitalization rates significantly decreased by 22.5% and 29.5%. TT significantly improved FEV1, FVC, and FEV1/FVC, saving 571/patient for society. Younger patients with asthma (18-44 years old) and patients with severe asthma (FEV1 < 60%) performed better upon the initiation of TT. Conclusions: TT reduced asthma exacerbations, improved lung function and reduced healthcare costs vs. DT, particularly in patients requiring systemic corticosteroids to treat severe exacerbations.

Filiaciones:
Plaza, V:
 Hosp Sant Creu i Sant Pau, Serv Neumol & Alergia, Barcelona 08025, Spain

Domínguez-Ortega, J:
 La Paz Univ Hosp, Inst Hlth Res IdiPAZ, Dept Allergy, Madrid 28046, Spain

Alsina, DGS:
 Chiesi Espana, Barcelona 08908, Spain

Lo Re, D:
 Univ Granada, Fac Pharm, Dept Med & Organ Chem, 18071 Granada, Spain

Sicras-Mainar, A:
 Atrys Hlth SA, Madrid 28002, Spain
ISSN: 14248247





Pharmaceuticals
Editorial
MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 16 Número: 11
Páginas:
WOS Id: 001114543500001
ID de PubMed: 38004474
imagen gold

MÉTRICAS